Biocept Inc. (BIOCQ)
Market Cap | 262.00 |
Revenue (ttm) | 1.36M |
Net Income (ttm) | -30.61M |
Shares Out | n/a |
EPS (ttm) | -50.90 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | n/a |
Open | n/a |
Previous Close | n/a |
Day's Range | n/a |
52-Week Range | n/a |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About BIOCQ
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications... [Read more]
Financial Performance
In 2022, Biocept's revenue was $25.86 million, a decrease of -57.78% compared to the previous year's $61.25 million. Losses were -$32.09 million, 1036.2% more than in 2021.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/b/4/press5-2072527.jpg)
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with bre...
![](https://cdn.snapi.dev/images/v1/m/s/press7-2055257.jpg)
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing a...
![](https://cdn.snapi.dev/images/v1/n/v/conf16-2049160.jpg)
Biocept to Participate in the H.C. Wainwright Global Investment Conference
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that management will particip...
![](https://cdn.snapi.dev/images/v1/o/m/conf2-2037522.jpg)
Biocept to Hold Business Update Conference Call on August 30, 2023
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business u...
![](https://cdn.snapi.dev/images/v1/q/v/press7-2022441.jpg)
Biocept Reports Second Quarter 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30...
![](https://cdn.snapi.dev/images/v1/a/u/press5-2021414.jpg)
Biocept's CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that its CNSid...
![](https://cdn.snapi.dev/images/v1/o/g/press18-1971228.jpg)
Biocept Announces the Passing of Board Chair M. Faye Wilson
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”) announces that M. Faye Wilson, Board Chair, passed away unexpectedly on Monday, July 10. The Board ...
![](https://cdn.snapi.dev/images/v1/e/n/press17-1941368.jpg)
Biocept Names Antonino Morales as President and Chief Executive Officer
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, has named Antonino Moral...
![](https://cdn.snapi.dev/images/v1/o/a/conf18-1934532.jpg)
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces that management will present a...
![](https://cdn.snapi.dev/images/v1/r/q/press18-1920579.jpg)
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept's CNSide™ Versus Cytology
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CNSide--Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces a poster pre...
![](https://cdn.snapi.dev/images/v1/a/z/press6-1906611.jpg)
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an underwritten...
![](https://cdn.snapi.dev/images/v1/o/v/press3-1894861.jpg)
Biocept Announces One-for-Thirty Reverse Stock Split
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that ...
![](https://cdn.snapi.dev/images/v1/t/b/press11-1883527.jpg)
Biocept Reports First Quarter 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 ...
![](https://cdn.snapi.dev/images/v1/7/u/press4-1840412.jpg)
Biocept Reports 2022 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 ...
![](https://cdn.snapi.dev/images/v1/7/6/press16-1811271.jpg)
Enrollment Begins in FORESEE Clinical Trial Using Biocept's CNSide™ to Evaluate Patients with Leptomeningeal Metastases
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical tr...
![](https://cdn.snapi.dev/images/v1/i/a/press14-1776697.jpg)
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purc...
![](https://cdn.snapi.dev/images/v1/9/9/press18-1698084.jpg)
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has en...
![](https://cdn.snapi.dev/images/v1/v/x/press3-1646905.jpg)
Biocept Reports Third Quarter 2022 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended Sept...
![](https://cdn.snapi.dev/images/v1/b/z/press17-1643481.jpg)
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Dir...
![](https://cdn.snapi.dev/images/v1/x/4/press18-1639525.jpg)
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a collaboration agreement to participate in an investiga...
![](https://cdn.snapi.dev/images/v1/t/q/press12-1631423.jpg)
Biocept Reports Second Quarter 2022 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June ...
![](https://cdn.snapi.dev/images/v1/1/q/conf3-1588777.jpg)
Biocept to Present at the LD Micro Main Event XV
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV...
![](https://cdn.snapi.dev/images/v1/l/n/press13-1584802.jpg)
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of CNSide for patien...
![](https://cdn.snapi.dev/images/v1/1/q/press8-1582844.jpg)
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held today, October 14 at 1 p.m...
![](https://cdn.snapi.dev/images/v1/m/u/press2-1571776.jpg)
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held October 14 at 1 p.m. Easte...